. Overview We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH 3 Table of Contents associated with interstitial lung disease, or PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of indu...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001728117-26-000017 | EDGAR | 94K words |
| 2025-03-13 | 2024-12-31 | 0001728117-25-000021 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001728117-24-000019 | EDGAR | — |
| 2023-03-17 | 2022-12-31 | 0001728117-23-000010 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001728117-22-000019 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001728117-21-000019 | EDGAR | — |
| 2020-03-24 | 2019-12-31 | 0001564590-20-012323 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001564590-19-009031 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001728117-25-000081 | EDGAR | 22K words |
| 2025-08-05 | 2025-06-30 | 0001728117-25-000068 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001728117-25-000036 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001728117-24-000092 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001728117-24-000085 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001728117-24-000056 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001728117-23-000134 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001728117-23-000108 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001728117-23-000049 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001728117-22-000100 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001728117-22-000085 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001728117-22-000047 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001728117-26-000018 | EDGAR | 2K words |
| 2026-02-23 | 0001728117-26-000004 | EDGAR | — |
| 2025-11-05 | 0001728117-25-000082 | EDGAR | — |
| 2025-09-25 | 0001728117-25-000076 | EDGAR | — |
| 2025-08-05 | 0001728117-25-000069 | EDGAR | — |
| 2025-06-25 | 0001728117-25-000043 | EDGAR | — |
| 2025-06-16 | 0001728117-25-000040 | EDGAR | — |
| 2025-05-15 | 0001728117-25-000037 | EDGAR | — |
| 2025-03-13 | 0001728117-25-000022 | EDGAR | — |
| 2025-02-19 | 0001728117-25-000004 | EDGAR | — |
113 total filings indexed. 83 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001728117 |
| Ticker | GOSS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gossamerbio.com |
| Listed | 2019-02-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report